Discontinuation of supply of a batch of medicines (with list)

According to the document, some enterprises due to production line transformation, production stoppage and other reasons, drugs have been unable to guarantee supply, submitted an application to cancel their products in Guizhou Province drug centralized procurement winning bid (hanging net) qualification, and promised that from the date of cancellation, the enterprise with the same product regulations products for two years may not participate in the centralized drug procurement activities in Guizhou Province.
A total of 22 drugs were disqualified from winning the bid (hanging net), and are basically large varieties of commonly used varieties, including injection of yan amber, cephalosporinecapsules, raw pulse drinks, involving Taiji Group Chongqing Chinese Medicine Co., Ltd., Southwest Pharmaceutical Co., Ltd., Suzhou Second Leaf Pharmaceutical Co., Ltd. and other well-known pharmaceutical companies.
, in recent years, drug companies to apply for the withdrawal of the network of frequent incidents, and are related to the national unity of non-supply commitment letter.
July 22, Ningxia Public Resources Trading Service Center issued a "notice on the publicity of the proposed cancellation of some production enterprises of drugs winning the bid (hanging net) qualification."
a total of 103 pharmaceutical companies in the past year put forward applications for the scrapping (revocation) of the relevant drugs, and the qualification of the above-above enterprises for the registration of the winning bid was cancelled.
a total of 261 drugs were removed from the network, involving ibuprofen dispersion tablets, hot yanning particles, blood plug-through tablets, compound three or seven blood supplements, hexa-flavored yellow pills, Grezit tablets, chloretamine tablets, temishatan tablets , cephalosporatin capsules, hydrochloric acid LOX fluorosa tablets, erythromycin capsules, azithromycin particles, libavelin particles, nimodi flat tablets, metformin tablets, metformin hydrochloride tablets and other commonly used chemical and Chinese medicine.
July 2, the Inner Mongolia Medical Insurance Bureau registered the "Notice on the summary publication of Texas German Pharmaceutical Co., Ltd. and other enterprises to apply for partial drug disqualification."
announcement shows that from March 1 to June 30, 2020, due to rising raw materials, production line transformation, drug approval was withdrawn and other reasons led to the cessation of production of many drugs, Texas De Pharmaceuticals, Wanbond Pharmaceutical Group Co., Ltd., 1 force Pharmaceutical Co., Ltd. a total of 20 pharmaceutical companies to Inner Mongolia to apply for the disqualification of 40 drugs, and submitted a unified national commitment not to supply.
On June 22, Gansu Province's centralized procurement network of pharmaceutical and medical supplies issued the withdrawal of the network, including musk live hemorrhoid cream, injection of creacoside, emergency syrup, compound catopri tablets and other 40 enterprises produced 68 drugs submitted the application to withdraw the network.
May 21, Shanxi Province drug centralized bidding procurement network issued two withdrawal notice, involving double yellow-linked particles, clearing the ling injection, hydrochloric acid Benapuri tablets, tobmycin eye drops, kramycin capsules and other common drugs 66 product rules actively applied for removal of the net.
maintain the national price system According to the documents issued by the provinces, rising costs, shortage of raw materials, production line transformation are the main reasons leading to drug production stoppages, stop supply.
, in recent years, drug price reduction is an irreversible trend in the pharmaceutical industry, drug prices gradually appear new lows, even to the floor price.
Some manufacturers in order to obtain the market, failed to take into account the national linkage, and therefore also broke the price system of their own products;
To API as an example, the media has repeatedly exposed the price of API prices "shocking", such as injection of calcium glucosate RAW drugs, sales prices rose 19 times to 54.6 times in three years;
At the level of Chinese medicine, directly corresponding to the rising prices of Chinese herbal medicines, especially the newly revised drug management law formally implemented, the quality requirements of Chinese medicine species are more stringent, resulting in downstream production enterprises difficult to use sub-standard varieties to sub-charge, but also indirectly promote the price of high-quality medicinal materials.
In addition, some pharmaceutical companies should consider the national market price, give up some provinces with smaller market share, to maintain the national price system, such as Inner Mongolia, Qinghai, Gansu drug capacity, market share is relatively small, enterprises consider the strategic abandonment, but also part of the overall product price strategy.
view in the U.S. industry that the withdrawal of scrapping labels may also be the preparation of pharmaceutical companies to raise prices after the resumption of production.
does this affect your business? For pharmaceutical enterprises, if the production enterprises can not supply drugs normally, they will face severe punishment;
To Gansu Province, for example, "Gansu Province drug centralized procurement integrity management measures" shows that the price below the cost of malicious bidding, or after winning the bid within 1 year can not guarantee supply, the exclusive winning bid or the lowest bid after the cost of upside down and other reasons do not guarantee supply, disrupt the market order;
the same product regulation accumulated 3 bad records or notification of criticism, warnings, bad records of the number of times the total is greater than or equal to 10 times, cancel the product rules of the hanging network.
the same enterprise has more than 2 (including 2) product regulations to cancel the hanging network, enterprises are blacklisted, the enterprise may not participate in the next round of centralized drug procurement activities in Gansu Province.
There is only one winning bid, the product regulation 3 bad records or notification of criticism, warning, bad record of the total is greater than or equal to 12 times, cancel the product regulations of the hanging network, enterprises blacklisted, the variety may not participate in the next round of centralized drug procurement activities in Gansu Province.
therefore, the two harms of the right to take its light, pharmaceutical enterprises will choose to actively scrap the standard, bear relatively light penalties, will not affect the other varieties of the pharmaceutical enterprises.
But it should be noted that the national collection, provincial collection and local collection of three layers of nested power, drug price reduction has been an inevitable trend, which also more test the cost control ability of enterprises.
future, strong cost control capacity, large core varieties, high market share, by virtue of cost advantages to seize the market enterprises, it will be easier to survive, which is also the direction of enterprise transformation.
.